Fully human monoclonal antibody inhibitors of the neonatal Fc receptor (FcRn) reduce circulating IgG in nonhuman primates

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Nixon, Andrew E ^a   Chen, Jie ^a   Sexton, Daniel J ^a   Muruganandam, Arumugam ^a   Bitonti, Alan J ^b   Dumont, Jennifer ^b   Viswanathan, Malini ^a   Martik, Diana ^a   Wassaf, Dina ^a   Mezo, Adam ^b   Wood, Clive R ^a   Biedenkapp, Joseph C ^a   TenHoor, Christopher ^a  

^a Dyax Corp   (United States)

^b Syntonix Pharmaceuticals   (United States)

Author keywords

Antibody engineering; Autoimmune disease; FcRn; IgG; Neonatal Fc receptor; Phage display

Indexed keywords

ALBUMIN; DX 2504; DX 2507; FC RECEPTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CATABOLISM; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; MACACA FASCICULARIS; MALE; MORTALITY; MOUSE; NEPHELOMETRY; NONHUMAN; SURFACE PLASMON RESONANCE; TRANSIENT TRANSFECTION;

EID: 84926648089     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00176     Document Type: Article

References (62)

1. Sesarman A, Vidarsson G, Sitaru C. The neonatal Fc receptor as therapeutic target in IgGmediated autoimmune diseases. Cellular and molecular life sciences: CMLS (2010) 67(15):2533-50. doi: 10.1007/s00018-010-0318-6. PubMed PMID: 20217455.
2. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Therapeutic advances in hematology (2013) 4(1):59-72. doi: 10.1177/2040620712464509. PubMed PMID: 23610614; PubMed Central PMCID: PMC3629762.
3. Teitel JM, Sholzberg M. Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies. Blood reviews (2013) 27(2):103-9. doi: 10.1016/j.blre.2013.02.003. PubMed PMID: 23452718.
4. Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annual review of genomics and human genetics (2012) 13:307-35. doi: 10.1146/annurev-genom-090711-163739. PubMed PMID: 22970722.
5. Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert opinion on investigational drugs (2009) 18(4):491-500. doi: 10.1517/13543780902832679. PubMed PMID: 19335277.
6. Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, et al. Bortezomib for refractory autoimmunity in pediatrics. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation (2014) 20(10):1654-9. doi: 10.1016/j.bbmt.2014.06.032. PubMed PMID: 24979732.
7. Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmunity reviews (2014) 13(6):685-96. doi: 10.1016/j.autrev.2014.01.053. PubMed PMID: 24468415.
8. Sieb JP. Myasthenia gravis: an update for the clinician. Clinical and experimental immunology (2014) 175(3):408-18. doi: 10.1111/cei.12217. PubMed PMID: 24117026; PubMed Central PMCID: PMC3927901.
9. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases (2011) 15(1):e2-16. doi: 10.1016/j.ijid.2010.03.025. PubMed PMID: 21074471.
10. Rituxan® (rituximab) Full Prescribing Information (August 2014). Genentech, Inc. South San Francisco, CA.
11. Arzerra® (ofatumumab) Full Prescribing Information (April 2014). Glaxo Group Limited. Brentford, United Kingdom.
12. Soliris® (eculizumab) Full Prescribing Information (April 2014). Alexion Pharmaceuticals, Inc. Cheshire, CT.
13. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. The New England journal of medicine (1982) 306(21):1254-8. doi: 10.1056/NEJM198205273062102. PubMed PMID: 6803159.
14. Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helvetica paediatrica acta (1981) 36(1):81-6. PubMed PMID: 6785258.
15. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nature reviews Immunology (2013) 13(3):176-89. doi: 10.1038/nri3401. PubMed PMID: 23411799.
16. Liew WK, Powell CA, Sloan SR, Shamberger RC, Weldon CB, Darras BT, et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA neurology (2014) 71(5):575-80. doi: 10.1001/jamaneurol.2014.17. PubMed PMID: 24590389.
17. Braun N, Bosch T. Immunoadsorption, current status and future developments. Expert opinion on investigational drugs (2000) 9(9):2017-38. doi: 10.1517/13543784.9.9.2017. PubMed PMID: 11060790.
18. Furst D, Felson D, Thoren G, Gendreau RM. Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Prosorba Trial Investigators. Therapeutic apheresis: official journal of the International Society for Apheresis and the Japanese Society for Apheresis (2000) 4(5):363-73 PubMed PMID: 11111818.
19. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2011) 76(3):294-300. doi: 10.1212/WNL.0b013e318207b1f6. PubMed PMID: 21242498; PubMed Central PMCID: PMC3034395.
20. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. The New England journal of medicine (2001) 345(10):747-55. doi: 10.1056/NEJMra993360. PubMed PMID: 11547745.
21. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nature reviews Immunology (2007) 7(9):715-25. doi: 10.1038/nri2155. PubMed PMID: 17703228.
22. Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, et al. Neonatal Fc receptor: from immunity to therapeutics. Journal of clinical immunology (2010) 30(6):777-89. doi: 10.1007/s10875-010-9468-4. PubMed PMID: 20886282; PubMed Central PMCID: PMC2970823.
23. Brambell FW, Hemmings WA, Morris IG. A Theoretical Model of Gamma-Globulin Catabolism. Nature (1964) 203:1352-4. PubMed PMID: 14207307.
24. Rodewald R. pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. The Journal of cell biology (1976) 71(2):666-9. PubMed PMID: 11223; PubMed Central PMCID: PMC2109747.
25. Wallace KH, Rees AR. Studies on the immunoglobulin-G Fc-fragment receptor from neonatal rat small intestine. The Biochemical journal (1980) 188(1):9-16. PubMed PMID: 7406892; PubMed Central PMCID: PMC1162530.
26. Simister NE, Rees AR. Isolation and characterization of an Fc receptor from neonatal rat small intestine. European journal of immunology (1985) 15(7):733-8. doi: 10.1002/eji.1830150718. PubMed PMID: 2988974.
27. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. European journal of immunology (1996) 26(3):690-6. doi: 10.1002/eji.1830260327. PubMed PMID: 8605939.
28. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrowderived cells functions to protect serum IgG from catabolism. Journal of immunology (2007) 179(7):4580-8. PubMed PMID: 17878355.
29. Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proceedings of the National Academy of Sciences of the United States of America (2008) 105(27):9337-42. doi: 10.1073/pnas.0801717105. PubMed PMID: 18599440; PubMed Central PMCID: PMC2453734.
30. Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proceedings of the National Academy of Sciences of the United States of America (2009) 106(8):2788-93. doi: 10.1073/pnas.0810796106. PubMed PMID: 19188594; PubMed Central PMCID: PMC2650344.
31. West AP, Jr., Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry (2000) 39(32):9698-708. PubMed PMID: 10933786.
32. Andersen JT, Dee Qian J, Sandlie I. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. European journal of immunology (2006) 36(11):3044-51. doi: 10.1002/eji.200636556. PubMed PMID: 17048273.
33. Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. The Journal of experimental medicine (2003) 197(3):315-22. PubMed PMID: 12566415; PubMed Central PMCID: PMC2193842.
34. Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry (2006) 45(15):4983-90. doi: 10.1021/bi052628y. PubMed PMID: 16605266.
35. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clinical pharmacology and therapeutics (2008) 84(5):548-58. doi: 10.1038/clpt.2008.170. PubMed PMID: 18784655.
36. Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. mAbs (2011) 3(5):422-30. doi: 10.4161/mabs.3.5.16983. PubMed PMID: 22048693; PubMed Central PMCID: PMC3225846.
37. Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao SW, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Critical reviews in biotechnology (2013). doi: 10.3109/07388551.2013.834293. PubMed PMID: 24156398.
38. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. Journal of immunology (2010) 184(4):1968-76. doi: 10.4049/jimmunol.0903296. PubMed PMID: 20083659.
39. Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. The Journal of clinical investigation (2004) 113(9):1328-33. doi: 10.1172/JCI18838. PubMed PMID: 15124024; PubMed Central PMCID: PMC398424.
40. Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. The Journal of clinical investigation (2005) 115(12):3440-50. doi: 10.1172/JCI24394. PubMed PMID: 16284651; PubMed Central PMCID: PMC1280965.
41. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, et al. The MHC class Ilike IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. Journal of immunology (2003) 170(7):3528-33. PubMed PMID: 12646614.
42. Ballow M. Mechanisms of immune regulation by IVIG. Current opinion in allergy and clinical immunology (2014) 14(6):509-15. doi: 10.1097/ACI.0000000000000116. PubMed PMID: 25337683.
43. Crow AR, Suppa SJ, Chen X, Mott PJ, Lazarus AH. The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia. Blood (2011) 118(24):6403-6. doi: 10.1182/blood-2011-08-374223. PubMed PMID: 22001393.
44. Christianson GJ, Sun VZ, Akilesh S, Pesavento E, Proetzel G, Roopenian DC. Monoclonal antibodies directed against human FcRn and their applications. mAbs (2012) 4(2):208-16. doi: 10.4161/mabs.4.2.19397. PubMed PMID: 22453095; PubMed Central PMCID: PMC3361656.
45. Mezo AR, McDonnell KA, Hehir CA, Low SC, Palombella VJ, Stattel JM, et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proceedings of the National Academy of Sciences of the United States of America (2008) 105(7):2337-42. doi: 10.1073/pnas.0708960105. PubMed PMID: 18272495; PubMed Central PMCID: PMC2268137.
46. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, et al. Enhanced halflife of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. International immunology (2006) 18(12):1759-69 doi: 10.1093/intimm/dxl110. PubMed PMID: 17077181.
47. Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nature biotechnology (2005) 23(10):1283-8. doi: 10.1038/nbt1143. PubMed PMID: 16186811.
48. Liu L, Garcia AM, Santoro H, Zhang Y, McDonnell K, Dumont J, et al. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. Journal of immunology (2007) 178(8):5390-8. PubMed PMID: 17404325.
49. Olaru F, Luo W, Suleiman H, St John PL, Ge L, Mezo AR, et al. Neonatal Fc receptor promotes immune complex-mediated glomerular disease. Journal of the American Society of Nephrology: JASN (2014) 25(5):918-25. doi: 10.1681/ASN.2013050498. PubMed PMID: 24357670; PubMed Central PMCID: PMC4005300.
50. Wassaf D, Kuang G, Kopacz K, Wu QL, Nguyen Q, Toews M, et al. High-throughput affinity ranking of antibodies using surface plasmon resonance microarrays. Analytical biochemistry (2006) 351(2):241-53. doi: 10.1016/j.ab.2006.01.043. PubMed PMID: 16510109.
51. Jostock T, Vanhove M, Brepoels E, Van Gool R, Daukandt M, Wehnert A, et al. Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries. Journal of immunological methods (2004) 289(1-2):65-80. doi: 10.1016/j.jim.2004.03.014. PubMed PMID: 15251413.
52. Sexton DJ, Chen T, Martik D, Kuzmic P, Kuang G, Chen J, et al. Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases. The Biochemical journal (2009) 422(2):383-92. doi: 10.1042/BJ20090010. PubMed PMID: 19527222.
53. Hoet RM, Cohen EH, Kent RB, Rookey K, Schoonbroodt S, Hogan S, et al. Generation of highaffinity human antibodies by combining donor-derived and synthetic complementarity-determiningregion diversity. Nature biotechnology (2005) 23(3):344-8. doi: 10.1038/nbt1067. PubMed PMID: 15723048.
54. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Advanced drug delivery reviews (2006) 58(5-6):686-706. doi: 10.1016/j.addr.2006.03.011. PubMed PMID: 16839640.
55. Wang W. Protein aggregation and its inhibition in biopharmaceutics. International journal of pharmaceutics (2005) 289(1-2):1-30. doi: 10.1016/j.ijpharm.2004.11.014. PubMed PMID: 15652195.
56. Sand KM, Dalhus B, Christianson GJ, Bern M, Foss S, Cameron J, et al. Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies. The Journal of biological chemistry (2014) 289(24):17228-39. doi: 10.1074/jbc. M113.522565. PubMed PMID: 24764301; PubMed Central PMCID: PMC4059163.
57. Proetzel G, Roopenian DC. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods (2014) 65(1):148-53. doi: 10.1016/j.ymeth.2013.07.005. PubMed PMID: 23867339; PubMed Central PMCID: PMC3858440.
58. Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry (1995) 34(45):14649-57. PubMed PMID: 7578107.
59. Neuber T, Frese K, Jaehrling J, Jager S, Daubert D, Felderer K, et al. Characterization and screening of IgG binding to the neonatal Fc receptor. mAbs (2014) 6(4):928-42. doi: 10.4161/mabs.28744. PubMed PMID: 24802048.
60. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis and rheumatism (2010) 62(6):1755-62. doi: 10.1002/art.27435. PubMed PMID: 20191576.
61. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. The New England journal of medicine (2006) 355(17):1772-9 doi: 10.1056/NEJMoa062930. PubMed PMID: 17065638.
62. Auerbach R, Bystryn JC. Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris. Archives of dermatology (1979) 115(6):728-30. PubMed PMID: 453877.